Tag Directory / REPRODUCTIVEHEALTH     showing 21–27 of 27   RSS



Preeclampsia could be treated with 'blood filtering' therapy, early study hints

livescience - A blood-filtering therapy for preeclampsia is safe for pregnant patients and their babies, according to a new pilot study.

AI Summary: Early clinical work suggests removing a circulating anti‑angiogenic factor can safely extend pregnancies in severe preeclampsia. Researchers used targeted extracorporeal filtration to lower soluble Fms‑like tyrosine kinase‑1 (sFlt‑1) levels, improving maternal and fetal stability long enough to delay delivery and reduce immediate risks, meriting larger controlled trials.

2 months / medicalxpress

2 months / medicalxpress

2 months / livescience

2 months / medicalxpress




Erectile disorder: How science is moving beyond Viagra

medicalxpress - Erectile disorder (ED) refers to a persistent difficulty achieving or maintaining an erection sufficient for satisfying sexual activity. It affects millions of men worldwide, including up to 1 in 4 in the United States. Beyond physical functioning, erecti…

AI Summary: Researchers are advancing alternatives to sildenafil-era approaches for erectile disorder, exploring new biological targets and therapies that aim to restore function rather than just patch symptoms. The coverage explains emerging mechanisms, investigational treatments and the shifting clinical landscape—because sometimes a Band-Aid on performance isn’t the long-term plan.

2 months / medicalxpress




FDA updates mifepristone safety study status

Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…

AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.

2 months / abcnews

2 months / medicalxpress




'I'm not being listened to' - new health plan launched as women say they are still ignored

bbc - New plans to improve healthcare for women and girls have been set out, but will they change anything?

AI Summary: Health officials unveiled a new women's health plan, but many women say the rollout feels performative and that their concerns remain unheard. Patient advocates warn the initiative risks repeating past mistakes unless it embeds lived experience, transparent accountability and genuine co-design—otherwise it's policy theater with a glossy brochure.

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress

2 months / medicalxpress

2 months / bbc

2 months / medicalxpress




FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

esmo - Evidence for efficacy is based on the findings from the ROSELLA study

AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.

2 months / oncodaily

2 months / oncodaily

2 months / esmo

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

3 months / oncodaily

3 months / esmo

3 months / oncodaily




Lost in space: Sperm struggles to navigate during weightless sex

medicalxpress - Scientists have used a tiny plastic "obstacle course" to test how much sperm would struggle to navigate during sex in the weightlessness of space.

AI Summary: New research shows sperm struggle to navigate and function in weightless conditions, suggesting microgravity could impair fertilization and complicate human reproduction beyond low-Earth orbit. Scientists warn these findings raise practical and biological questions for long-duration missions and potential colonization efforts, prompting calls for more reproductive biology studies in space.

3 months / livescience

3 months / livescience

3 months / discovermagazine

3 months / medicalxpress

3 months / livescience




Teens are driving the demand for online abortion pills via telehealth

medicalxpress - Teens in the U.S. are obtaining medication abortion pills through telehealth, and young people aged 18 to 24 are ordering medication abortion at much higher rates than older adults.

AI Summary: Telehealth provision of medication abortion has surged, reducing travel for many and prompting a noticeable uptick in online requests from teenagers. Reports show virtual care is reshaping access patterns and forcing healthcare systems and regulators to confront new realities around remote prescribing, confidentiality, and youth access to reproductive services.

3 months / medicalxpress

3 months / npr / Kate Wells

3 months / medicalxpress

3 months / abcnews

3 months / medicalxpress

3 months / fiercehealthcare




Back to Top


REPRODUCTIVEHEALTH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Oncology, Olfaction, Medicare Advantage (not listed), Supply Chain and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.